67 related articles for article (PubMed ID: 25319885)
1. Analysis of changes in phosphorylation of receptor tyrosine kinases: antibody arrays.
Rani S; O'Driscoll L
Methods Mol Biol; 2015; 1233():15-23. PubMed ID: 25319885
[TBL] [Abstract][Full Text] [Related]
2. Analysis of receptor tyrosine kinase (RTK) phosphorylation by immunoblotting.
McDermott M; O'Donovan N
Methods Mol Biol; 2015; 1233():3-14. PubMed ID: 25319884
[TBL] [Abstract][Full Text] [Related]
3. Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors.
Corcoran C; O'Driscoll L
Methods Mol Biol; 2015; 1233():169-80. PubMed ID: 25319899
[TBL] [Abstract][Full Text] [Related]
4. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
5. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
6. Identification of receptor protein tyrosine phosphatases (RPTPs) as regulators of receptor tyrosine kinases (RTKs) using an RPTP siRNA-RTK substrate screen.
Lee H; Bennett AM
Methods Mol Biol; 2015; 1233():111-20. PubMed ID: 25319894
[TBL] [Abstract][Full Text] [Related]
7. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
[TBL] [Abstract][Full Text] [Related]
8. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Albini A; Cesana E; Donatelli F; Cammarota R; Bucci EO; Baravelli M; Anzà C; Noonan DM
Future Cardiol; 2011 Sep; 7(5):693-704. PubMed ID: 21929348
[TBL] [Abstract][Full Text] [Related]
9. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.
Harbinski F; Craig VJ; Sanghavi S; Jeffery D; Liu L; Sheppard KA; Wagner S; Stamm C; Buness A; Chatenay-Rivauday C; Yao Y; He F; Lu CX; Guagnano V; Metz T; Finan PM; Hofmann F; Sellers WR; Porter JA; Myer VE; Graus-Porta D; Wilson CJ; Buckler A; Tiedt R
Cancer Discov; 2012 Oct; 2(10):948-59. PubMed ID: 22874768
[TBL] [Abstract][Full Text] [Related]
10. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases.
Ahmad F; Goldstein BJ
J Cell Biochem; 1997 Jan; 64(1):117-27. PubMed ID: 9015760
[TBL] [Abstract][Full Text] [Related]
11. Quantification of the effects of mutations on receptor tyrosine kinase (RTK) activation in mammalian cells.
He L; Hristova K
Methods Mol Biol; 2015; 1233():81-7. PubMed ID: 25319891
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the dimerization profiles of HER tyrosine kinases by time-resolved Förster resonance energy transfer (TR-FRET).
Lopez-Crapez E; Ho-Pun-Cheung A; Garnero P; Bazin H
Methods Mol Biol; 2015; 1233():45-55. PubMed ID: 25319888
[TBL] [Abstract][Full Text] [Related]
13. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
17. Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.
Lundholm L; Hååg P; Juntti T; Lewensohn R; Viktorsson K
Int J Radiat Biol; 2014 Aug; 90(8):718-26. PubMed ID: 24646078
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.
Montero JC; Seoane S; Pandiella A
Cell Signal; 2013 Nov; 25(11):2281-9. PubMed ID: 23899556
[TBL] [Abstract][Full Text] [Related]
19. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
20. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]